Biotech Values

[jbog]

You might be right, we should see some data soon.

It seems hard to believe that with M923 being on the verge of FDA submittal, wouldn't be carrying an premium for this asset.

Not only did Shire give it back, they paid to give it back. They ended the agreement prior to the recent FDA guidance so maybe they really screwed up. For some reason I doubt it.